Fut, nem toboroz3. fázis
Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)
Key facts
- Where
- Angelholm, Eksjo, Helsingborg, Jonkoping, Landskrona, Malmo, Orebro, Varnamo és Vaxjo, SvédországSee the 9 sites
- Phase
- 3. fázis
Where in Svédország
- Region Skane Angelholms SjukhusAngelholm, SvédországNo longer taking part
- Region Joenkoepings LaenEksjo, SvédországNo longer taking part
- Region Skane Helsingborg HospitalHelsingborg, SvédországNo longer taking part
- Region Joenkoepings LaenJonkoping, SvédországNo longer taking part
- Region Skane Lasarettet I LandskronaLandskrona, SvédországNo longer taking part
- Region Skane Skanes UniversitetssjukhusMalmo, SvédországNo longer taking part
- Region Oerebro LaenOrebro, SvédországNo longer taking part
- Region Joenkoepings LaenVarnamo, SvédországNo longer taking part
- Region KronobergVaxjo, SvédországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Skane
- Trial code
- EU 2023-504945-30-00
- Record updated
- 2024. augusztus 30.
- Original description
Investigate if adjuvant gemcitabine improves recurrence free survival compared to adjuvant mitomycinRead full original descriptionShow less
Investigate if adjuvant gemcitabine improves recurrence free survival compared to adjuvant mitomycin
Inclusion: Primary and recurrent non muscle invasive bladder cancer with intermediate risk of recurrence.
Exclusion: Known allergy to either mitomycin or gemcitabine; Age below 18 years of age; lack of informed consent; Severe incontinence; Cronic urethral catheter.